Côté, Julie http://orcid.org/0000-0003-1383-2984
LeBlanc, Richard
Mian, Hira http://orcid.org/0000-0003-1584-1067
Chu, Michael P.
McCurdy, Arleigh http://orcid.org/0000-0002-8809-4368
Masih-Khan, Esther
Su, Jiandong
Jimenez-Zepeda, Victor H.
Song, Kevin
Louzada, Martha
White, Darrell
Sebag, Michael
Reiman, Anthony
Stakiw, Julie
Kotb, Rami
Bergstrom, Debra
Aslam, Muhammad
Kaedbey, Rayan
Venner, Christopher P.
Gul, Engin http://orcid.org/0000-0002-3922-3215
Reece, Donna
Article History
Received: 19 April 2023
Revised: 4 August 2023
Accepted: 23 August 2023
First Online: 5 September 2023
Competing interests
: J.C. has received honoraria from Janssen and Sanofi, and research funding from Janssen. H.M. has received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK, and she also received the HHS Research Early Career Award from Hamilton Health Sciences Foundation. D.R. has received research funding from Otsuka, Celgene, Janssen, Takeda, Merck, BMS and Millennium, and she served as a consultant for Celgene, Jansen, Amgen, Karyopharm and Takeda. She also received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK. A.M. has received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK. V.H.J-Z. has received honoraria from Celgene, Janssen, Takeda, Merck and BMS. K.S. has received research funding from Celgene, and honoraria from Celgene, Janssen, Amgen and Takeda. M.L. has received honoraria from Janssen, Celgene, Amgen and Pfizer. R.L. served as a consultant for BMS, Janssen, Amgen, Sanofi and FORUS Therapeutics, and received honoraria from Pfizer. M.S. has a membership on an entity’s Board of Directors or advisory committees for Janssen, Amgen, Takeda and Celgene. J.S. has received honoraria from Janssen, FORUS Therapeutics, BMS, Pfizer, Sanofi and Amgen. R.Ko. has received honoraria from Akcea, Amgen, BMS, Janssen, Merck, Sanofi, Celgene, Pfizer and Takeda, and research funding from Merck and Sanofi. He also declares a current equity holder in the private company Karyopharm. R.Ka. served as a consultant for Janssen, BMS, Sanofi, FORUS, Beigene and Pfizer, and has received honoraria from BMS and Janssen. D.W. has received honoraria from Amgen, Antengene, Celgene, Janssen, Karyopharm, Sanofi and Takeda. C.V. has received honoraria from Janssen, Takeda, FORUS, BMS, Abbvie, Sanofi, GSK and Pfizer. All remaining authors declare no competing interests.